E-drug: NSAIDS - do they differ?
------------------------------
Dear e-druggers,
Meloxicam is been advertised as having a lower incidence of
adverse GI events when compared with piroxicam, naproxen, and diclofenac,
among others. The main evidence seems to come from a meta-analysis
published in 1996 in the Brit J Rheumatology. Besides guiding clinical
decisions in high risk patients, this may have implications from the
societal economic viewpoint when selecting an NSAID as the additional
adquisition costs may in theory be offset by the savings generated due to
less GI events.
Has anybody looked recently at this issue of different and
contrasting profiles in risk of GI events among NSAIDS, specifically with
meloxicam?
Sincerely,
Rodolfo Dennis
Clinical Epidemiology Unit
Javeriana University, Bogota, Colombia.
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.